Mohd Anas Shaikh, Dr. Jaya Agnihotri, Saba Khan
Recent developments in sustained-release drug delivery systems (SRDDS) aim to improve patient compliance while improving the safety and efficacy of the drug molecule by developing a convenient dose form. In the current research, the tablet was formulated with immediate-release granules of pioglitazone and sustained-release granules of caffeine. Sustained release granules for tablets were prepared using Compritol 888 ATO polymer in ratio with PVP (K30 and K90) that retard the release of drug from the tablet and for improvement of patient compliance. The sustained-release tablets were prepared by the wet granulation method. The formulated tablet was subjected to tests like thickness, friability, weight variation, hardness, drug content, in-vitro release study, and stability study. A drug and polymer compatibility study were performed by FTIR. Out of all the batches prepared the optimized batch (B4) is selected based on the concentration of Compritol 888 ATO with PVP-K90 is increased it showed better drug release as Compritol 888 ATO is a release retardant. The in-vitro drug release was found to be more than 90% after 12 hours. This release retardant (Compritol 888 ATO) at the optimized concentration formed a desired matrix with the PVP it showed and action with the combination of pioglitazone and caffeine proved to be a promising approach to antidiabetic action.